Skip to content

Zavegepant

    Brands

    DAE Class; Rx

    Common Brand Names; Zavzpret

    • CGRP Receptor Antagonists

    Intranasal calcitonin gene-related peptide receptor antagonist
    Used for the acute treatment of migraine with or without aura
    Safety of treating more than 8 migraines/30 days not established

    Indicated for acute treatment of migraine with or without aura

    History of hypersensitivity to zavegepant or other ingredients

    >10%

    Taste disorder (18%)

    1-10%

    Nausea (4%)

    Nasal discomfort (3%)

    Vomiting (2%)

    <1%

    Hypersensitivity, including facial swelling and urticaria

    Hypersensitivity reactions reported, including facial swelling and urticaria; initiate appropriate therapy if hypersensitivity occurs

    Ask patient to discuss prescription, OTC medications, or herbal supplements that they take or plan to take

    Drug interaction overview

    • Substrate of OATP1B3 and NTCP
    • OATP1B3 or NTCP inhibitors
      • Avoid coadministration
      • Inhibitors of organic anion transporting polypeptide 1B3 (OATP1B3) or sodium taurocholate cotransporting polypeptide (NTCP) transporters may significantly increase zavegepant exposure
    • OATP1B3 or NTCP inducers
      • Avoid coadministration
      • Inducers of OATP1B3 or NTCP transporters may decrease zavegepant exposure
    • Intranasal decongestants
      • Dosage modification
      • Avoid coadministration; if unavoidable, administer intranasal decongestants at least 1 hr after zavegepant
      • Coadministration may decrease systemic exposure and efficacy of zavegepant

    Pregnancy

    Data are not available on developmental risk associated with the use in pregnant females

    Lactation

    Data are unavailable regarding the presence of zavegepant or its metabolites in human milk, effects on breastfed infants, or effects on milk production

    Adults

    10 mg/day intranasally.

    Geriatric

    10 mg/day intranasally.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Zavegepant

    intranasal solution

    • 10mg/spray